122 related articles for article (PubMed ID: 37066339)
1. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in
Corr BR; Moroney MR; Woodruff E; Watson ZL; Jordan KR; Danhorn T; Bailey C; Wolsky RJ; Bitler BG
bioRxiv; 2023 Apr; ():. PubMed ID: 37066339
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
[TBL] [Abstract][Full Text] [Related]
3. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
Tam BY; Chiu K; Chung H; Bossard C; Nguyen JD; Creger E; Eastman BW; Mak CC; Ibanez M; Ghias A; Cahiwat J; Do L; Cho S; Nguyen J; Deshmukh V; Stewart J; Chen CW; Barroga C; Dellamary L; Kc SK; Phalen TJ; Hood J; Cha S; Yazici Y
Cancer Lett; 2020 Mar; 473():186-197. PubMed ID: 31560935
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
5. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
Murai A; Ebara S; Sasaki S; Ohashi T; Miyazaki T; Nomura T; Araki S
PLoS One; 2020; 15(10):e0240718. PubMed ID: 33064779
[TBL] [Abstract][Full Text] [Related]
6. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
Shafer A; Zhou C; Gehrig PA; Boggess JF; Bae-Jump VL
Int J Cancer; 2010 Mar; 126(5):1144-54. PubMed ID: 19688827
[TBL] [Abstract][Full Text] [Related]
8. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
9. Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer
O'Donnell J; Zhao Z; Buckingham L; Hao T; Suo H; Zhang X; Fan Y; John C; Deng B; Shen X; Sun W; Secord AA; Zhou C; Bae-Jump VL
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503790
[TBL] [Abstract][Full Text] [Related]
10. Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.
Jeong YG; Katuwal NB; Kang MS; Ghosh M; Hong SD; Park SM; Kim SG; Kim TH; Moon YW
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835582
[TBL] [Abstract][Full Text] [Related]
11. The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
Berger AA; Kawaler EA; Dao F; Misirlioglu S; Fernandez EA; Olvera N; Van Oudenhove E; DeLair D; Levine DA
Gynecol Oncol; 2022 Nov; 167(2):323-333. PubMed ID: 36150916
[TBL] [Abstract][Full Text] [Related]
12. Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4.
Schmitt C; Miralinaghi P; Mariano M; Hartmann RW; Engel M
ACS Med Chem Lett; 2014 Sep; 5(9):963-7. PubMed ID: 25221649
[TBL] [Abstract][Full Text] [Related]
13. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
14. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential.
Martín Moyano P; Němec V; Paruch K
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066143
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells
Kuittinen T; Rovio P; Staff S; Luukkaala T; Kallioniemi A; Grénman S; Laurila M; Mäenpää J
Anticancer Res; 2017 Dec; 37(12):6575-6581. PubMed ID: 29187432
[TBL] [Abstract][Full Text] [Related]
16. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
17. Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.
Chandra V; Rai R; Benbrook DM
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066052
[TBL] [Abstract][Full Text] [Related]
18. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling.
Lin Y; Chen X; Lin L; Xu B; Zhu X; Lin X
Cell Mol Biol Lett; 2024 May; 29(1):63. PubMed ID: 38698330
[TBL] [Abstract][Full Text] [Related]
19. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
